1. Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Recruiting MPN Trials
PHAZAR
(Interventional)
Accelerated or blast phase MPN
PI: Prof Claire Harrison
A Phase 1b Study to assess the safety and tolerability of oral Ruxolitinib in combination with Azacitidine in patients with Advanced Phase MPN, including MDS or AML arising from MPN
Eligibility Criteria:
-Age 16 and over, Diagnosis of ET,PV or MF with either bone marrow blasts (with or without dysplastic changes) or >20% bone marrow blasts, ECOG performance status:0-3.
CAMBRIDGE
(Observational)
The Causes of Clonal Blood Cell Disorders
Patients with clonal haematological disorders.
MEASURES
All MPN
PI: Dr Deepti Radia
The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) Trial: Serial Assessment of Symptomatic Response to Non Experimental Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms
-All MPN patients starting a new, therapeutic intervention.
TAMARIN
Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms
-PV,ET,MF stable disease on hydroxurea, bilirubin or ruxolutinib. No prior thrombosis. Age over 60, men aged between may be considered, women must be post-menopausal.
BLU
Systemic mastocytosis
A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
-Age 18 over and have an ECOG performance status of 0-3.
Part 1 of study: Patients with advSM or other relapsed or refractory myeloid malignancy.
Part 2 of study: Patients are split into 3 groups-ASM,SM,AHNMD and MCL
MPN Trials in Set-up
INCYTE
INCB
(Interventional)
Myeloid lymphoid disorders with 8p11
PI Prof C Harrison
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Eligibility Criteria: Age 18 and over, lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation and subjects who are not candidates for stem cell transplantation but have progressed, will be eligible.
ACE-536
Myelofibrosis
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence
Eligibility Criteria: -Age 18 or over, subject has MPN-associated myelofibrosis, subject has anemia and an ECOG performance score ≤2. Includes patients currently on ruxolitinib, but may also not be on the drug
INCB
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Eligibility Criteria: -Age 18 or over, confirmed diagnosis of PMF,PPV-MF or PET-MF, palpable spleen of more than or equal to 5cm, life expectancy of at least 24 weeks
PAC203
An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib
Eligibility Criteria: -Diagnosed with PMF, prior ruxolitinib treatment failure, palpable splenomegaly of more than or equal to 5cm, peripheral blast count of less than 10%.
MPN Clot
(Observational)
PVor ET
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: influence on the clot structure.
Eligibility Criteria: -All men and women, older than 18 years, with a diagnosis of PV or ET (primary or secondary
Navitoclax (ABT-263)
A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis.
Eligibility Criteria: -Age 18 and over, diagnosis of primary MF,PPV_MF or PET_MF, ineligible or unwilling to undergo stem cell transplantation, Subjects must have received ruxolitinib therapy for at least 24 weeks and be on a stable dose of more than 10mg BID of ruxolitinib more than 8 weeks prior to 1st dose of navitoclax, ECOG of 0.1 or 2.
Haematology Research contact details
Professor Claire Harrison
Tel:
Dr Deepti Radia
Tel:
Dr Donal Mclornan
General Enquiries